Anticipates Securing Leading Position in Early Diagnosis and Preventive Healthcare Market for Cancer, Dementia, and Other Intractable Diseases
Global health tech company Molecular You (MYCo) and NK cell therapy research biotech NKCL Bio Group Co., Ltd. (NKCL) signed a Memorandum of Understanding (MOU) for mutual business cooperation at NKCL's headquarters. This agreement focuses on the two companies collaborating to introduce MYCo's innovative AI-based preventive healthcare and premium healthcare technologies into Korea and expand platform services within the Korean market. Specifically, the two companies jointly agreed to invest a total of $35 million (approximately KRW 48.7 billion) into NKCL through a third-party overseas investment institution. This investment is intended to support NKCL's cell therapy development and the adoption and application of MYCo's preventive medicine platform technology. This collaboration is expected to serve as a catalyst for strengthening the partnership between the two companies and expanding into the Korean and global markets.
Innovation-Driven Companies: Molecular You and NKCL Bio Group
MYCo is a North American health tech company headquartered in Canada and the United States. MYCo's proprietary multi-omics platform specializes in supporting preventive medicine by accurately predicting health risks before symptoms appear. The MYCo platform, based on Multi-Omics (a revolutionary analytical method that comprehensively and simultaneously analyzes data generated at the molecular level—including genomics, transcriptomics, proteomics, metabolomics, epigenomics, and lipidomics) enables the simultaneous, comprehensive, and integrated analysis of data generated at the molecular level to predict disease. The MYCo platform quantifies over 280 high-value blood-based proteins and metabolites using AI-supported algorithms, providing clinicians with exceptional insights into health risks, associated biological pathways, and actionable plans to support patient health recovery. This platform is recognized for opening new horizons in preventive medicine by detecting early molecular-level signs of diseases and symptoms such as cancer, dementia, rheumatoid arthritis, inflammatory bowel disease, and cardiovascular disease.
NKCL Bio Group is a leading South Korean biotech company focused on developing immune cell therapies utilizing natural killer (NK) cells. NK cells play a pivotal role in our immune system by directly seeking out and destroying cancer cells or abnormal cells. NKCL is dedicated to research maximizing the mass production and therapeutic efficacy of NK cell therapies based on its proprietary technology.
Creating Synergy: Combining Early Diagnosis and Immunotherapy
This collaboration is expected to generate powerful synergy by combining MYCo's disease prediction and prevention technology with NKCL's therapeutic technology. Utilizing MYCo's platform to preemptively identify the likelihood of diseases like cancer or dementia, and then treating these diseases with NKCL's NK cell therapies in a personalized manner, while continuously monitoring and managing treatment progress, will enable the provision of an integrated solution. This model goes beyond merely treating diseases; it can significantly contribute to enhancing public health and reducing national healthcare budgets through fundamental prevention and post-treatment management.
An NKCL representative stated, “We are pleased to introduce an innovative solution to Korea's preventive healthcare market through our collaboration with MYCo,” adding, “By combining our respective strengths, we will present a new paradigm for overcoming intractable diseases like cancer and dementia.”
Dr. Rob Fraser, Co-founder, CEO, and CSO of MYCo, remarked, “It is a great honor to collaborate with a pioneering and innovative NK cell therapy company like NKCL. This partnership presents a significant opportunity for MYCo to successfully launch its business in Korea. By integrating our globally leading technologies, we will build a lasting relationship to provide innovative healthcare solutions to the Korean people.”
Future Vision: Leading the Global Healthcare Market
This agreement goes beyond a simple business collaboration between two companies; it will serve as a crucial stepping stone for the Korean bio industry to strengthen its competitiveness in the global market. The combination of MYCo's technological capabilities and NKCL's clinical and therapeutic expertise is expected to secure a unique position in the fields of precision medicine and personalized preventive healthcare.
Furthermore, the two companies anticipate that jointly developing an AI-based bio-healthcare big data platform business model will create a successful case study. By integrating MYCo's precision molecular data with NKCL's immune cell data, they aim to achieve innovative advancements in disease prediction and personalized treatment development.
https://www.mkhealth.co.kr/news/articleView.html?idxno=75205
